Lipids and lipidomics in brain injury and diseases

AAPS Journal

Volumn 8, Issue 2, 2006, Pages

  Adibhatla, Rao Muralikrishna ^a,b,c,d   Hatcher, J F ^a   Dempsey, R J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Cardiovascular Research Center   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

10,17S docosatriene; 4 hydroxynonenal; Acrolein; Arachidonic acid; CDP choline; Cerebral ischemia; Citicoline; Cytidine 5' diphosphocholine; Docosahexaenoic acid; ESI MS MS; Lipid peroxidation; Lipidomics; MALDI TOF; Neuroprotectin D1; Phospholipases; Phospholipids; Reactive oxygen species; RNA silencing; siRNA; Small interfering RNA; Stroke

Indexed keywords

CARDIOLIPIN; CYTOCHROME C; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; LIPID; NEUROPROTECTIN D1; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIOINFORMATICS; BIPOLAR DISORDER; BRAIN DISEASE; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; ELECTROSPRAY MASS SPECTROMETRY; ENERGY METABOLISM; GAS CHROMATOGRAPHY; GENE SILENCING; GLUCOSE METABOLISM; HEALTH CARE COST; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; LIPID PEROXIDATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR BIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NIEMANN PICK DISEASE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; BRAIN; BRAIN DISEASES; BRAIN INJURIES; GENOMICS; HUMANS; LIPIDS;

EID: 33646812935     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080236     Document Type: Review

References (76)

1. Piomelli D. The challenge of brain lipidomics. Prostaglandins Other Lipid Mediat. 2005;77:23-34.
2. Fahy E, Subramaniam S, Brown HA, et al. A comprehensive classification system for lipids. J Lipid Res. 2005;46:839-862.
3. Wenk MR. The emerging field of lipidomics. Nat Rev Drug Discov. 2005;4:594-610.
4. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry. 2001;40:4893-4903.
5. Peterson BL, Cummings BS. A review of chromatographic methods for the assessment of phospholipids in biological samples. Biomed Chromatogr. 2006;20:227-243.
6. Balazy M. Eicosanomics: targeted lipidomics of eicosanoids in biological systems. Prostaglandins Other Lipid Mediat. 2004;73:173-180.
7. Hillard CJ. Lipids and drugs of abuse. Life Sci. 2005;77:1531-1542.
8. van Meer G. Cellular lipidomics. EMBO J. 2005;24:3159-3165.
9. Rapaka RS, Piomelli D, Spiegel S, Bazan N, Dennis EA. Targeted lipidomics: signaling lipids and drugs of abuse. Prostaglandins Other Lipid Mediat. 2005;77:223-234.
10. Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke. 2005;36:118-123.
11. Forrester JS, Milne SB, Ivanova PT, Brown HA. Computational lipidomics: a multiplexed analysis of dynamic changes in membrane lipid composition during signal transduction. Mol Pharmacol. 2004;65:813-821.
12. Han X, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J Lipid Res. 2003;44:1071-1079.
13. Han X, Yang J, Cheng H, Yang K, Abendschein DR, Gross RW. Shotgun lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered substrate utilization with mitochondrial dysfunction. Biochemistry. 2005;44:16684-16694.
14. Hunt AN, Fenn HC, Clark GT, Wright MM, Postle AD, McMaster CR. Lipidomic analysis of the molecular specificity of a cholinephosphotransferase in situ. Biochem Soc Trans. 2004;32:1060-1062.
15. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 2003;278:43807-43817.
16. Brugger B, Erben G, Sandhoff R, Wieland FT, Lehmann WD. Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc Natl Acad Sci USA. 1997;94:2339-2344.
17. Pulfer M, Murphy RC. Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev. 2003;22:332-364.
18. Schiller J, Suss R, Arnhold J, et al. Matrix-assisted laser desorption and ionization time-of-flight (MALDI-TOF) mass spectrometry in lipid and phospholipid research. Prog Lipid Res. 2004;43:449-488.
19. Fisher M, Brott TG. Emerging therapies for acute ischemic stroke: new therapies on trial. Stroke. 2003;34:359-361.
20. Siao CJ, Fernandez SR, Tsirka SE. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci. 2003;23:3234-3242.
21. Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke. 2001;32:2376-2381.
22. 2, hydroxyl radicals and lipid peroxidation in transient cerebral ischemia. Antioxid Redox Signal. 2003;5:647-654.
23. 2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res. 2003;73:308-315.
24. 2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med. 2006;40:376-387.
25. 2 and CTP-phosphocholine cytidylyltransferase after stroke. J Biol Chem. 2006;281:6718-6725.
26. Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79:1431-1568.
27. 4: role in transient cerebral ischemia of gerbils. Neurochem Res. 1999;24:1225-1232.
28. Rao AM, Hatcher JF, Dempsey RJ. CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. J Neurosci Res. 1999;58:697-705.
29. Rao AM, Hatcher JF, Dempsey RJ. Lipid metabolism in ischemic neuronal death. Recent Res Develop Neurochem. 1999;2:533-549.
30. Rao AM, Hatcher JF, Dempsey RJ. Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection. J Neurochem. 2000;75:2528-2535.
31. Rao AM, Hatcher JF, Dempsey RJ. Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res. 2001;893:268-272.
32. Sastry PS, Rao KS. Apoptosis and the nervous system. J Neurochem. 2000;74:1-20.
33. Adibhatla RM, Hatcher JF. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005; 30:15-23.
34. Ter Horst GJ, Korf J, eds. Clinical Pharmacology of Cerebral Ischemia. Totowa, NJ: Humana; 1997.
35. Choi DW. Methods for antagonizing glutamate neurotoxicity. Cerebrovasc Brain Metab Rev. 1990;2:105-147.
36. Bazan NG. Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res. 2003;44:2221-2233.
37. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005;15:159-166.
38. Bazan NG, Marcheselli VL, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci. 2005;1053:137-147.
39. Lukiw WJ, Cui J-G, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774-2783.
40. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA. 2004;101:8491-8496.
41. Cui Z, Houweling M. Phosphatidylcholine and cell death. Biochim Biophys Acta. 2002;1585:87-96.
42. Freeman EJ, Terrian DM, Dorman RV. Presynaptic facilitation of glutamate release from isolated hippocampal mossy fiber nerve endings by arachidonic acid. Neurochem Res. 1990;15:743-750.
43. 2+ availability in isolated mossy fiber nerve endings. Neurochem Res. 1997;22:1215-1222.
44. Jayadev S, Linardic CM, Hannun YA. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to TNF-α. J Biol Chem. 1994;269:5757-5763.
45. Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. Trends Biochem Sci. 1995;20:73-77.
46. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
47. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochim Biophys Acta. 1998;1436:233-243.
48. Kinloch RA, Treherne JM, Furness LM, Hajimohamadreza I. The pharmacology of apoptosis. Trends Pharmacol Sci. 1999;20:35-42.
49. Goswami R, Dawson G. Does ceramide play a role in neural cell apoptosis? J Neurosci Res. 2000;60:141-149.
50. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandezcheca JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species - role of mitochondrial glutathione. J Biol Chem. 1997;272:11369-11377.
51. Ghafourifar P, Klein SD, Schucht O, et al. Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state. J Biol Chem. 1999;274:6080-6084.
52. Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis - the role of cytochrome c. Biochim Biophys Acta. 1998;1366:139-149.
53. Cai J, Jones DP. Superoxide in apoptosis - mitochondrial generation triggered by cytochrome c loss. J Biol Chem. 1998;273: 11401-11404.
54. Hoch FL. Cardiolipins and biomembrane function. Biochim Biophys Acta. 1992;1113:71-133.
55. Nakahara I, Kikuchi H, Taki W, et al. Degradation of mitochondrial phospholipids during experimental cerebral ischemia in rats. J Neurochem. 1991;57:839-844.
56. Nakahara I, Kikuchi H, Taki W, et al. Changes in major phospholipids of mitochondria during postischemic reperfusion in rat brain. J Neurosurg. 1992;76:244-250.
57. Rimon G, Bazenet CE, Philpott KL, Rubin LL. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563-570.
58. Suzuki S, Furushiro M, Takahashi M, Sakai M, Kudo S. Oral administration of soybean lecithin transphosphatidylated phosphatidylserine (SB-tPS) reduces ischemic damage in the gerbil hippocampus. Jpn J Pharmacol. 1999;81:237-239.
59. Katsuki H, Okuda S. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol. 1995;46:607-636.
60. Kruman I, Brucekeller AJ, Bredesen D, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J Neurosci. 1997;17:5089-5100.
61. Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein - potential markers for oxidative stress. Proc Natl Acad Sci USA. 1998;95:4882-4887.
62. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem. 1999;72:751-756.
63. Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res. 2002;70:133-139.
64. Adibhatla RM, Hatcher JF, Dempsey RJ. Cytidine-5′-diphosphocholine (CDP-choline) affects CTP:phosphocholine cytidylyltransferase and lyso-phosphatidylcholine after transient brain ischemia. J Neurosci Res. 2004;76:390-396.
65. 2 enzymes. Foreword. Biol Pharm Bull. 2004;27:1157.
66. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. In press.
67. Urabe T, Hattori N, Yoshikawa M, Yoshino H, Uchida K, Mizuno Y. Colocalization of Bcl-2 and 4-hydroxynonenal modified proteins in microglial cells and neurons of rat brain following transient focal ischemia. Neurosci Lett. 1998;247:159-162.
68. 1 pyramidal neurons precedes delayed neuronal damage in the gerbil brain. Neuroscience. 2000;100:241-250.
69. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E. Acrolein is a product of lipid peroxidation reaction - formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem. 1998;273:16058-16066.
70. Tomitori H, Usui T, Saeki N, et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke. 2005;36:2609-2613.
71. Liu X, Lovell MA, Lynn BC. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal Chem. 2005;77:5982-5989.
72. Cejka D, Losert D, Wacheck V. Short interfering RNA (siRNA): tool or therapeutic? Gin Sci (Lond). 2006;110:47-58.
73. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541-552.
74. Wang L, Magdaleno S, Tabas I, Jackowski S. Early embryonic lethality in mice with targeted deletion of the CTP:phosphocholine cytidylyltransferase alpha gene (Pcyt1a). Mol Cell Biol. 2005;25:3357-3363.
75. Klein J. Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem. 2005;94:1473-1487.
76. Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/ sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. FASEB J. 2003;17:1411-1421.